氯沙坦对维持性血透患者心血管保护作用的临床观察

目的 :观察氯沙坦对行维持性血透治疗的慢性肾功能衰竭 (CRF)患者心血管保护作用。方法 :6 0例维持性血透患者 (血肌酐≥ 70 0 μmol·L- 1 ) ,治疗组 (给予氯沙坦 5 0～ 10 0mg·d- 1 )及对照组 (给予非血管紧张素受体拮抗剂和非ACEI类降压药 )各 30例 ,记录用药前后各组患者血压 ,运用多普勒组织成像 (DTI)技术观察用药前后两组患者二尖瓣环峰值收缩速度 (VS)、收缩时间速度积分 (TVIS)、舒张早期速度 (VE)、舒张晚期速度 (VA)、VE VA 比值。结果 :治疗组及对照组患者治疗后血压均明显下降 ,二尖瓣环VS、TVIS、VE、VE VA ,则均明显上升 ;治疗组与对照组血压分别在治疗前、后相比并无明显差异 ;治疗前两组间二尖瓣环VS、TVIS、VE、VE VA 并无显著性差异 ,但在治疗12个月后 ,治疗组二尖瓣环VS、TVIS、VE、VE VA 则明显高于对照组。结论 :氯沙坦对行持续性血透的CRF患者具有良好的心脏保护作用 ,可有效改善其心功能 ,且不依赖于其降压作用

The Clinical Study of Protection of Cardial Function in Patients by Consecutive Hemodialysis Treated with Losartan

Objective: To observe the protection of cardial function in patients with chronic renal failure(CRF) when treated with Losartan. Methods: In 60 patients with CRF in consecutive hemodialysis, group of treatment with Losartan included 30 patients and others were in group of controls. Blood pressure (BP)of each patients was recorded before and after treatment. Doppler tissue imaging (DTI) was performed to record V S,TVI S, V E,V A,V E/V A of mitral annulus before and after treatment. Results: After treatment, BP of the two groups decreased and V S,TVI S,V E,V E/V A increased significantly than before. Before and after treatment, there was no significant difference in BP between the two groups; before treatment, there was no difference in V S,TVI S,V E,V E/V A of the two groups, but after treatment, V S,TVI S,V E,V E/V A in group of treatment were significant greater than those of group of controls. Conclusion: There is good protection of cardiac and improvement of cardial function in patients with CRF when treated by Losartan, and these action do not depend on the function of reduction of BP.